Leatt (LEAT) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
20 Nov, 2025Opening remarks and agenda
Meeting commenced at 10:00 A.M. EDT, chaired remotely by the CEO and CFO, with officers and directors introduced from multiple locations.
Agenda included summary and nominations for two proposals, a Q&A session, and voting.
Stockholders were notified in advance, with participation instructions provided via press release and proxy statement.
Board and executive committee updates
Officers present included the CEO/CFO, Chairman, Director/Audit Committee Chair, and US Securities Consultant.
Independent inspector and meeting secretary roles were confirmed.
Shareholder proposals
Two proposals were presented: election of directors and ratification of the independent auditor.
Management's slate for directors included Dr. Christopher Leatt, Jeffrey Joseph Guzy, and Sean MacDonald.
M&K CPAs, PLLC was proposed as the independent auditor for the fiscal year ending December 31, 2025.
Latest events from Leatt
- 41% revenue growth and 248% net income increase highlight robust 2025 performance.LEAT
Q4 202524 Mar 2026 - Directors and auditors were approved by strong majorities, with no shareholder questions.LEAT
AGM 20243 Feb 2026 - Q2 revenue fell 18% as distributor sales lagged, but direct channels and liquidity improved.LEAT
Q2 20241 Feb 2026 - Q3 2024 saw modest revenue growth and margin gains, but net income fell sharply.LEAT
Q3 202418 Jan 2026 - Q4 revenue up 14% and margins improved, but full-year sales and profit declined.LEAT
Q4 202425 Dec 2025 - Annual meeting to elect directors and ratify auditors, with focus on governance and transparency.LEAT
Proxy Filing2 Dec 2025 - Annual meeting set for July 1, 2025, to elect directors and ratify the auditor.LEAT
Proxy Filing2 Dec 2025 - Q1 2025 revenue up 45%, net income positive, global sales and margins drive growth.LEAT
Q1 202525 Nov 2025 - Q2 2025 revenue up 61%, net income up 208%, with robust growth and improved margins.LEAT
Q2 202524 Nov 2025